| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/17425255.2017.1239718 |
| P698 | PubMed publication ID | 27678284 |
| P50 | author | Elizabeth A Shephard | Q47160999 |
| P2093 | author name string | Ian R Phillips | |
| P2860 | cites work | The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein | Q22004271 |
| Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism | Q22251223 | ||
| Identification of active flavin-containing monooxygenase isoform 2 in human lung and characterization of expressed protein | Q24292035 | ||
| Cloning, primary sequence and chromosomal localization of human FMO2, a new member of the flavin-containing mono-oxygenase family | Q24294247 | ||
| Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine | Q24317369 | ||
| Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics | Q24539077 | ||
| Genetic variability at the human FMO1 locus: significance of a basal promoter yin yang 1 element polymorphism (FMO1*6) | Q28182512 | ||
| Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans | Q28184203 | ||
| Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans | Q28203039 | ||
| 6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3 | Q28205470 | ||
| Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011 | Q28207926 | ||
| Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450 | Q28215954 | ||
| Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression | Q28216584 | ||
| The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase | Q28217168 | ||
| Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1'-oxide | Q28250108 | ||
| Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome | Q28256555 | ||
| Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication | Q28267159 | ||
| The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development | Q28267391 | ||
| S-oxygenation of the thioether organophosphate insecticides phorate and disulfoton by human lung flavin-containing monooxygenase 2. | Q45007440 | ||
| In vitro metabolism of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl) phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor alpha/gamma agonist. I. Role of cytochrome P450, methyltransferases, | Q45023504 | ||
| Assessment of the N-oxidation of deprenyl, methamphetamine, and amphetamine enantiomers by chiral capillary electrophoresis: an in vitro metabolism study. | Q45047656 | ||
| Flavin-containing monooxygenase activity can be inhibited by nitric oxide-mediated S-nitrosylation | Q45055964 | ||
| Benzydamine metabolism in vivo is impaired in patients with deficiency of flavin-containing monooxygenase 3. | Q45163414 | ||
| Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis | Q45205080 | ||
| Enantioselective in-line and off-line CE methods for the kinetic study on cimetidine and its chiral metabolites with reference to flavin-containing monooxygenase genetic isoforms | Q46089936 | ||
| Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-Dihydropyridin-4-one catalyzed by non-P450 enzymes | Q46298070 | ||
| Expression in Escherichia coli of the flavin-containing monooxygenase D (form II) from adult human liver: determination of a distinct tertiary amine substrate specificity | Q46353859 | ||
| Involvement of liver aldehyde oxidase in the reduction of nicotinamide N-oxide | Q46360741 | ||
| Cyclopropylamine inactivation of cytochromes P450: role of metabolic intermediate complexes | Q46409821 | ||
| In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions | Q46413696 | ||
| Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics | Q46537968 | ||
| Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin | Q46575106 | ||
| Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. | Q50736144 | ||
| Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3. | Q50933183 | ||
| Isolation and Culture of Mouse Hepatocytes: Gender-Specific Gene Expression Responses to Chemical Treatments. | Q50995522 | ||
| Metabolism and disposition of a selective alpha(7) nicotinic acetylcholine receptor agonist in humans. | Q51756285 | ||
| Hepatic metabolism of MK-0457, a potent aurora kinase inhibitor: interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase. | Q51913503 | ||
| In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism. | Q53555444 | ||
| Expression of recombinant human flavin monooxygenase and moclobemide-N-oxide synthesis on multi-mg scale. | Q54336662 | ||
| Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities. | Q54451067 | ||
| Prochiral sulfoxidation as a probe for multiple forms of the microsomal flavin-containing monooxygenase: studies with rabbit FMO1, FMO2, FMO3, and FMO5 expressed in Escherichia coli. | Q54632225 | ||
| Biocatalytic Characterization of Human FMO5: Unearthing Baeyer–Villiger Reactions in Humans | Q56879308 | ||
| Potential for drug interactions mediated by polymorphic flavin-containing monooxygenase 3 in human livers | Q59152985 | ||
| Some distinctions between flavin-containing and cytochrome P450 monooxygenases | Q36235997 | ||
| Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety | Q36252867 | ||
| Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development. | Q36316996 | ||
| Characterization of mouse flavin-containing monooxygenase transcript levels in lung and liver, and activity of expressed isoforms | Q36540754 | ||
| Metabolism and pharmacokinetics of the anti-tuberculosis drug ethionamide in a flavin-containing monooxygenase null mouse | Q36753612 | ||
| Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3. | Q36870689 | ||
| Metabolomics reveals the metabolic map of procainamide in humans and mice. | Q36880244 | ||
| RNA Sequencing Quantification of Xenobiotic-Processing Genes in Various Sections of the Intestine in Comparison to the Liver of Male Mice. | Q36947714 | ||
| Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes | Q37060764 | ||
| Flavin-containing monooxygenases: mutations, disease and drug response | Q37142726 | ||
| The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa | Q37152243 | ||
| Aryl hydrocarbon receptor-dependent induction of flavin-containing monooxygenase mRNAs in mouse liver | Q37214624 | ||
| The potential of knockout mouse lines in defining the role of flavin-containing monooxygenases in drug metabolism | Q37772507 | ||
| Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. | Q38024216 | ||
| Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities. | Q38097321 | ||
| Pharmacogenetics of olanzapine metabolism | Q38127716 | ||
| Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors | Q38510442 | ||
| What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? | Q38763388 | ||
| Alternative promoters and repetitive DNA elements define the species-dependent tissue-specific expression of the FMO1 genes of human and mouse | Q39253466 | ||
| An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model | Q39397094 | ||
| Flavin-containing monooxygenases: catalytic mechanism and substrate specificities | Q39654203 | ||
| The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes | Q40587197 | ||
| The olivacine derivative s 16020 (9-hydroxy-5,6-dimethyl-N-[2-(dimethylamino)ethyl)-6H-pyrido(4,3-B)-carbazole-1-carboxamide) induces CYP1A and its own metabolism in human hepatocytes in primary culture | Q40601665 | ||
| Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases | Q40908165 | ||
| Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes | Q41610819 | ||
| Effect of human flavin-containing monooxygenase 3 polymorphism on the metabolism of aurora kinase inhibitors | Q41618331 | ||
| In vitro metabolism of an estrogen-related receptor γ modulator, GSK5182, by human liver microsomes and recombinant cytochrome P450s. | Q41753964 | ||
| Human flavin-containing monooxygenase 2.1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide | Q41763477 | ||
| Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis | Q41995896 | ||
| Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes | Q42180308 | ||
| Studies on N-demethylation of methamphetamine by liver microsomes of guinea-pigs and rats: the role of flavin-containing mono-oxygenase and cytochrome P-450 systems | Q42250916 | ||
| Detoxication of tyramine by the flavin-containing monooxygenase: stereoselective formation of the trans oxime | Q42547874 | ||
| A rapid and sensitive CE method with field-enhanced sample injection and in-capillary derivatization for selenomethionine metabolism catalyzed by flavin-containing monooxygenases | Q42722567 | ||
| The phenotype of a flavin-containing monooyxgenase knockout mouse implicates the drug-metabolizing enzyme FMO1 as a novel regulator of energy balance | Q42803218 | ||
| In vitro metabolism studies of nomifensine monooxygenation pathways: metabolite identification, reaction phenotyping, and bioactivation mechanism | Q42994450 | ||
| Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities | Q44217913 | ||
| Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan | Q44365471 | ||
| Hepatotoxicity of ketoconazole in Sprague-Dawley rats: glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent binding | Q44440251 | ||
| Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies | Q44483223 | ||
| S-oxidation of S-methyl-esonarimod by flavin-containing monooxygenases in human liver microsomes | Q44741194 | ||
| Evaluation of xenobiotic N- and S-oxidation by variant flavin-containing monooxygenase 1 (FMO1) enzymes | Q44771795 | ||
| Gender differences in hepatic expression of flavin-containing monooxygenase isoforms (FMO1, FMO3, and FMO5) in mice | Q44862293 | ||
| Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases (Fmos). | Q44926024 | ||
| Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted | Q44986948 | ||
| Quantitative analysis of FMO gene mRNA levels in human tissues | Q28273925 | ||
| Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FM04 | Q28280814 | ||
| The molecular biology of the flavin-containing monooxygenases of man | Q28300051 | ||
| Role of hepatic flavin-containing monooxygenase 3 in drug and chemical metabolism in adult humans | Q28300061 | ||
| Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FM03 gene mutations in a Korean population | Q28374623 | ||
| Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism | Q28375739 | ||
| Physiological factors affecting protein expression of flavin-containing monooxygenases 1, 3 and 5 | Q28565273 | ||
| Multisubstrate flavin-containing monooxygenases: applications of mechanism to specificity | Q28679232 | ||
| Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. | Q33201366 | ||
| Transient trimethylaminuria related to menstruation | Q33270550 | ||
| Analysis of flavin-containing monooxygenase 3 genotype data in populations administered the anti-schizophrenia agent olanzapine | Q33428292 | ||
| In vitro and in vivo inhibition of human flavin-containing monooxygenase form 3 (FMO3) in the presence of dietary indoles | Q33875990 | ||
| Effect of various diets on the expression of phase-I drug-metabolizing enzymes in livers of mice | Q33894107 | ||
| Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes | Q33901684 | ||
| Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. | Q33929051 | ||
| Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity | Q33951756 | ||
| Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase | Q34140161 | ||
| Trimethylaminuria and a human FMO3 mutation database | Q34225073 | ||
| Inhibition of purified and membrane-bound flavin-containing monooxygenase 1 by (N,N-dimethylamino)stilbene carboxylates | Q34390394 | ||
| Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans | Q34439916 | ||
| St. John's wort and its constituent hyperforin concordantly regulate expression of genes encoding enzymes involved in basic cellular pathways | Q34458985 | ||
| Human flavin-containing monooxygenases | Q34482959 | ||
| In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine | Q34631507 | ||
| Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). | Q34691621 | ||
| N-oxygenation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by the rat liver flavin-containing monooxygenase expressed in yeast cells | Q34721316 | ||
| An overview of the mechanism, substrate specificities, and structure of FMOs | Q34818980 | ||
| Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation | Q34849013 | ||
| Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals | Q35001267 | ||
| The phenotype of a knockout mouse identifies flavin-containing monooxygenase 5 (FMO5) as a regulator of metabolic ageing | Q35871695 | ||
| Clinical utility gene card for: Trimethylaminuria - update 2014 | Q35959740 | ||
| In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms | Q36055300 | ||
| Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity | Q36055351 | ||
| Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption | Q36093134 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 167-181 | |
| P577 | publication date | 2016-09-29 | |
| P1433 | published in | Expert Opinion on Drug Metabolism & Toxicology | Q5421205 |
| P1476 | title | Drug metabolism by flavin-containing monooxygenases of human and mouse | |
| P478 | volume | 13 |
| Q57282958 | A Phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier |
| Q92019197 | Effects of fenbendazole and triclabendazole on the expression of cytochrome P450 1A and flavin-monooxygenase isozymes in bovine precision-cut liver slices |
| Q92229912 | Flavin-containing monooxygenases: new structures from old proteins |
| Q97590552 | Group-based pharmacogenetic prediction: is it feasible and do current NHS England ethnic classifications provide appropriate data? |
| Q41206250 | Identification of Flavin-Containing Monooxygenase 5 (FMO5) as a Regulator of Glucose Homeostasis and a Potential Sensor of Gut Bacteria |
| Q47107145 | Inactivation mechanism of N61S mutant of human FMO3 towards trimethylamine. |
| Q38604902 | Interspecies Variation of In Vitro Stability and Metabolic Diversity of YZG-331, a Promising Sedative-Hypnotic Compound |
| Q40097312 | Metabolism of F18, a Derivative of Calanolide A, in Human Liver Microsomes and Cytosol |
| Q98566142 | Regulation of dynamic pigment cell states at single-cell resolution |
| Q53233045 | The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance. |
| Q88732416 | Xanthates: Metabolism by Flavoprotein-Containing Monooxygenases and Antimycobacterial Activity |
Search more.